表紙
市場調查報告書

切除設備:醫療設備的開發平台評估 (2020年)

Ablation Equipments - Medical Devices Pipeline Assessment, 2020

出版商 GlobalData 商品編碼 346490
出版日期 內容資訊 英文 169 Pages
訂單完成後即時交付
價格
切除設備:醫療設備的開發平台評估 (2020年) Ablation Equipments - Medical Devices Pipeline Assessment, 2020
出版日期: 2020年02月15日內容資訊: 英文 169 Pages
簡介

與本報告提供全球切除設備的相關市場上之主要開發中產品 (醫療設備) 及其臨床實驗的進展調查,同時彙整產品特性比較分析 (臨床實驗的各進展階段) ,再加上主要企業簡介及代表性產品,近來的市場動靜 (資本交易·事業聯盟等) 等資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 切除設備概要

第3章 目前臨床實驗中的產品

  • 切除設備 - 開發中產品:各臨床實驗階段
  • 切除設備 - 開發中產品:各地區 (國家)
  • 切除設備 - 開發中產品:各法規途徑
  • 切除設備 - 開發中產品:各核准時期 (估計)
  • 切除設備 - 現在進行中的臨床實驗

第4章 切除設備:各企業目前臨床實驗中的開發中產品

  • 切除設備企業:各臨床實驗階段的開發中產品
  • 切除設備:各臨床實驗階段的開發中產品

第5章 切除設備的企業·產品概要

  • AngioDynamics Inc
    • 開發中產品及進行中的臨床實驗概要
  • Avenda Health Inc
  • CPSI Biotech
  • Creo Medical Ltd
  • Deneb Medical SL

第6章 切除設備市場:目前的趨勢

第7章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0910EPD

GlobalData's Medical Devices sector report, "Ablation Equipments - Medical Devices Pipeline Assessment, 2020" provides an overview of Ablation Equipments currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Incontinence Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Ablation Equipments under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Ablation Equipments and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Ablation Equipments under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Introduction

  • 2.1 Ablation Equipments Overview

3 Products under Development

  • 3.1 Ablation Equipments - Pipeline Products by Stage of Development
  • 3.2 Ablation Equipments - Pipeline Products by Territory
  • 3.3 Ablation Equipments - Pipeline Products by Regulatory Path
  • 3.4 Ablation Equipments - Pipeline Products by Estimated Approval Date
  • 3.5 Ablation Equipments - Ongoing Clinical Trials

4 Ablation Equipments - Pipeline Products under Development by Companies

  • 4.1 Ablation Equipments Companies - Pipeline Products by Stage of Development
  • 4.2 Ablation Equipments - Pipeline Products by Stage of Development

5 Ablation Equipments Companies and Product Overview

  • 5.1 AngioDynamics Inc Company Overview
    • 5.1.1 AngioDynamics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.2 Avenda Health Inc Company Overview
    • 5.2.1 Avenda Health Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.3 CPSI Biotech Company Overview
    • 5.3.1 CPSI Biotech Pipeline Products & Ongoing Clinical Trials Overview
  • 5.4 Creo Medical Ltd Company Overview
    • 5.4.1 Creo Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.5 Deneb Medical SL Company Overview
    • 5.5.1 Deneb Medical SL Pipeline Products & Ongoing Clinical Trials Overview

6 Ablation Equipments- Recent Developments

  • 6.1 Nov 19, 2019: Medtronic reports second quarter financial results for the year 2019
  • 6.2 Nov 15, 2019: Fractyl announces new data from Revita-1 clinical study showing durable benefits after a single treatment through two years of follow up
  • 6.3 Nov 14, 2019: Medtronic highlights leadership in inclusion, diversity, and equity in 2019 integrated performance report
  • 6.4 Nov 08, 2019: Fractyl announces Revita-2 data showing Revita DMR provides statistically significant improvements in blood glucose and liver fat in type 2 diabetes with and without NAFLD
  • 6.5 Nov 06, 2019: Olympus unveils corporate strategy

7 Appendix

  • 7.1 Methodology
  • 7.2 About GlobalData
  • 7.3 Contact Us
  • 7.4 Disclaimer

List of Tables

  • Table 1: Ablation Equipments - Pipeline Products by Stage of Development
  • Table 2: Ablation Equipments - Pipeline Products by Territory
  • Table 3: Ablation Equipments - Pipeline Products by Regulatory Path
  • Table 4: Ablation Equipments - Pipeline Products by Estimated Approval Date
  • Table 5: Ablation Equipments - Ongoing Clinical Trials
  • Table 6: Ablation Equipments Companies - Pipeline Products by Stage of Development
  • Table 7: Ablation Equipments - Pipeline Products by Stage of Development
  • Table 8: AngioDynamics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 9: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Product Status
  • Table 10: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Product Description
  • Table 11: Nanoknife System - Bladder Cancer - Product Status
  • Table 12: Nanoknife System - Bladder Cancer - Product Description
  • Table 13: NanoKnife System - Cervical Cancer - Product Status
  • Table 14: NanoKnife System - Cervical Cancer - Product Description
  • Table 15: NanoKnife System - Head And Neck Cancer - Product Status
  • Table 16: NanoKnife System - Head And Neck Cancer - Product Description
  • Table 17: NanoKnife System - Lung Cancer - Product Status
  • Table 18: NanoKnife System - Lung Cancer - Product Description
  • Table 19: Nanoknife System - Metastatic Lymph Nodes - Product Status
  • Table 20: Nanoknife System - Metastatic Lymph Nodes - Product Description
  • Table 21: NanoKnife System - Prostate Cancer - Product Status
  • Table 22: NanoKnife System - Prostate Cancer - Product Description
  • Table 23: NanoKnife System - Rectal Cancer - Product Status
  • Table 24: NanoKnife System - Rectal Cancer - Product Description
  • Table 25: Nanoknife System - Renal Pelvis Urothelial Neoplasms - Product Status
  • Table 26: Nanoknife System - Renal Pelvis Urothelial Neoplasms - Product Description
  • Table 27: NanoKnife System - Stage III Pancreatic Cancer - Product Status
  • Table 28: NanoKnife System - Stage III Pancreatic Cancer - Product Description
  • Table 29: Nanoknife System - Stomach Neoplasm - Product Status
  • Table 30: Nanoknife System - Stomach Neoplasm - Product Description
  • Table 31: AngioDynamics Inc - Ongoing Clinical Trials Overview
  • Table 32: NanoKnife System - Prostate Cancer - A Pilot Study in Human Subjects Evaluating the Use of the NanoKnife System for Ablation of Prostate Cancer Tissue in a Low and Intermediate Risk Patient Population
  • Table 33: NanoKnife System - Prostate Cancer - Efficacy and Safety Assessment of Nanoknife (AngyoDynamics, USA) for Irreversible Electroporation (IRE) of Localized Prostate Cancer
  • Table 34: NanoKnife System - Prostate Cancer - Examination of Focal Therapies - MR.pdfI-Fusion, HIFU, NanoKnife and Cryotherapy
  • Table 35: NanoKnife System - Prostate Cancer - Focal Irreversible Electroporation as Salvage Treatment in Radio-recurrent Prostate Cancer: A Prospective Multicenter Pilot Study
  • Table 36: NanoKnife System - Prostate Cancer - Irreversible Electroporation (IRE) for Unresectable Prostatic Neoplasms: Phase I and Phase II Clinical Trial
  • Table 37: NanoKnife System - Prostate Cancer - Multi-center Randomized Clinical Two Arm Intervention Study Evaluating Irreversible Electroporation for the Ablation of Localized Prostate Cancer
  • Table 38: NanoKnife System - Prostate Cancer - Registry of Irreversible Electroporation for the Ablation of Prostate Cancer with Use of Nanoknife Device; A Multi-center, International Registry to Evaluate the Treatment of Prostate Cancer in Terms of Recurrence, Functional Outcomes and Safety
  • Table 39: NanoKnife System - Stage III Pancreatic Cancer - A Clinical Research about Using Irreversible Electroporation to Treat Locally Advanced Pancreatic Cancer
  • Table 40: NanoKnife System - Stage III Pancreatic Cancer - A Pilot Study of Irreversible Electroporation for the Treatment of Upfront Resectable Pancreatic Cancer in the Head of the Pancreas
  • Table 41: NanoKnife System - Stage III Pancreatic Cancer - A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma
  • Table 42: NanoKnife System - Stage III Pancreatic Cancer - Ablation of Unresectable Locally Advanced Pancreatic Cancer with Nanoknife Irreversible Electroporation (IRE) System: Response and Tolerability
  • Table 43: NanoKnife System - Stage III Pancreatic Cancer - Assessing Optimal Treatment Settings for the Ablation of Locally Advanced Pancreatic Cancer with CT-guided Percutaneous Irreversible Electroporation (ANTILOPE): A Randomized Feasibility Study
  • Table 44: NanoKnife System - Stage III Pancreatic Cancer - Crossatlantic Randomized Controlled Trial Comparing Outcome in Survival after Systemic Plus Focal Therapy for Inoperable Pancreatic Carcinoma: Radiotherapy Versus Irreversible Electroporation: CROSSFIRE Trial
  • Table 45: NanoKnife System - Stage III Pancreatic Cancer - Evaluation of the Short and Intermediate Term Outcomes of Ablation of Locally Advanced Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System - A Prospective Study
  • Table 46: NanoKnife System - Stage III Pancreatic Cancer - Impact of Irreversible Electroporation on Quality of Life for Patients with Locally Advanced Pancreatic Cancer
  • Table 47: NanoKnife System - Stage III Pancreatic Cancer - Interest of Irreversible Electroporation in the Treatment of Pancreatic Adenocarcinoma
  • Table 48: NanoKnife System - Stage III Pancreatic Cancer - IRE: Anti-tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer
  • Table 49: NanoKnife System - Stage III Pancreatic Cancer - Irreversible Electroporation for Locally Advanced Pancreatic Ductal Adenocarcinoma (LEAP TRIAL): A Phase I/II Prospective Trial
  • Table 50: NanoKnife System - Stage III Pancreatic Cancer - Registry to Evaluate Effectiveness and Safety of the NanoKnife System for the Ablation of Stage 3 Pancreatic Adenocarcinoma
  • Table 51: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - A Prospective Clinical Trial Using Irreversible Electroporation (IRE) for the Treatment of Unresectable Hepatic Carcinoma Close to the Gallbladder
  • Table 52: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - A Prospective Clinical Trial Using Irreversible Electroporation for the Treatment of Liver Cancers
  • Table 53: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Colorectal Metastatic Liver Disease: Efficacy of Irreversible Electroporation (IRE) - A Phase II Clinical Trial: COLDFIRE-2 Study
  • Table 54: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Comparison Percutaneous Cryosurgery and Irreversible Electroportion in Unresectable Liver Cancer Close to Diaphragmatic Dome
  • Table 55: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Hepatic Carcinoma in Poor Liver Function: Safety and Efficacy of Irreversible Electroporation (IRE)
  • Table 56: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Irreversible Electroporation (IRE) for Unresectable Portal Venous Tumor Emboli: Phase I and Phase II Clinical Trial
  • Table 57: Nanoknife System - Renal Pelvis Urothelial Neoplasms - Irreversible Electroporation (IRE) for Unresectable Renal Pelvic and Ureteral Neoplasms: Phase I and Phase II Clinical Trial
  • Table 58: Nanoknife System - Metastatic Lymph Nodes - Irreversible Electroporation (IRE) for Unresectable Lymph Node Metastases: Phase I and Phase II Clinical Trial
  • Table 59: NanoKnife System - Lung Cancer - Irreversible Electroporation (IRE) For Lung Neoplasms Accompanied by Respiratory Function Insufficiency: Phase I and Phase II Clinical Trial
  • Table 60: Nanoknife System - Stomach Neoplasm - Irreversible Electroporation (IRE) for Unresectable Stomach Neoplasms: Phase I and Phase II Clinical Trial

List of Figures

  • Figure 1: Ablation Equipments - Pipeline Products by Stage of Development
  • Figure 2: Ablation Equipments - Pipeline Products by Territory
  • Figure 3: Ablation Equipments - Pipeline Products by Regulatory Path
  • Figure 4: Ablation Equipments - Pipeline Products by Estimated Approval Date
  • Figure 5: Ablation Equipments - Ongoing Clinical Trials